Zaks Tal Zvi 4

What Happened Zaks Tal Zvi, a director of TEVA Pharmaceutical Industries Ltd (TEVA), received a grant of 7,242 restricted share units (RSUs) on May 28, 2026. The RSUs are recorded as derivative awards at $0.00 per unit (no cash paid); reported value on the Form 4 is $0 because the units are contingent rights rather than immediate share purchases. This is a compensation award (not a market purchase or sale).

Key Details

• Transaction date and type: May 28, 2026 — Grant/Award of 7,242 restricted share units (coded A). Price reported: $0.00 per unit; total reported value: $0 (derivative).
• Vesting/settlement: RSUs granted May 28, 2026 and vest May 28, 2027 (see footnote).
• Shares owned after transaction: Not disclosed on the filing.
• Footnotes of note:
  • Each RSU represents a contingent right to receive one ordinary share (or, at the committee’s option, the cash value of one ordinary share).
  • RSUs vest on May 28, 2027.
  • Ordinary shares may be represented by American Depositary Shares (each currently represents one ordinary share).
• Filing timeliness: Form 4 filed June 1, 2026; this appears to meet the SEC’s two-business-day filing requirement for a May 28 transaction.

Context Restricted share units are a common form of equity compensation for executives and directors and represent a future right to shares or cash if vesting conditions are met; they are not an immediate purchase or sale and do not by themselves signal a buying or selling sentiment. For investors, the key dates are the grant and the vesting/settlement date — here, settlement is at least one year away (May 28, 2027).